Michigan AG pursues Lilly pricing investigation; rising spending on hepatitis B drugs

Taking stock of the drug industry, from the lab to the medicine chest  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by       STAT+: Michigan attorney general pursues investigation into Lilly's 'grossly' excessive insulin prices By Ed Silverman Kristoffer Tripplaar/AP The Michigan Attorney General wants to probe Eli Lilly's insulin pricing, which the state says is having a "devastating impact" on patients. Read More STAT+: Out-of-pocket spending for hepatitis B meds kept rising, despite generic competition By Ed Silverman CDC A competitive generic market should lead to lower drug prices. But a new study suggests in the case of hepatitis B drugs, that didn't happen. Read More The Biden administration used billions in hospital Covid-19 funds to pay drugmakers By Rachel Cohrs Alex Wong/Getty Images The administration took nearly $7 billion from a fund meant to help hospitals and clinics and used it to buy Covid vaccines and therapeutics. Read More Sponsor content by THE PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) Drug manufacturers pointing fingers…again… Over the past half decade, brand pharmaceutical manufacturers have undertaken a massive campaign to deflect blame for their pricing decisions. Ironically, the industry that controls the list price of prescription drugs has attempted to point the finger at those focused on reducing the cost of prescription drugs for patients and payers. We urge Congressional negotiators to continue to resist the latest attempts to shift the blame that puts profits over patients. STAT+: Insufficient progress is being made in reporting clinical trial results in the U.S. By Ed Silverman Molly Ferguson for STAT A new analysis finds that there has been insufficient progress on improving the reporting of clinical trial results. Read More STAT+: Future of Gilead blood cancer drug is clouded after studies are stopped due to safety issue By Adam Feuerstein Yichuan Cao/Sipa USA With the future of magrolimab now in doubt, pressure builds on Gilead to maximize the potential of its other cancer-focused acquisitions. Read More Wednesday, January 26, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser